Advertisement: KISS
ARM Innovation Hub
RealVNC mid banner careers
Advertisement: Mobas mid banner
Advertisement: CPL mid banner
Advertisement: Bridge Fibre mid
Barr Ellison Solicitors – commercial property
Advertisement: Bradfield Centre mid
RealVNC mid-banner general
Advertisement: Cambridge Network
Advertisement: mid banner EY
Advertisement: Lynch Wood Park
16 April, 2018 - 15:09 By Tony Quested

Horizon Discovery expands into livestock vaccines market

Cambridge’s global gene editing thought leader, Horizon Discovery, has made a significant move into the livestock vaccine market.

Horizon has struck a partnership with Pirbright Institute to support research into improvement of vaccine yields in this key segment of AgBio technology.

The research is supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation. The deal highlights Horizon’s extended biomanufacturing capabilities.

The development of efficient and affordable vaccines against viral diseases plays an important role in meeting the rapidly growing demand in the AgBio market, where global production is persistently reduced through viral infection and where the consequences of an outbreak can be devastating.

Many vaccines are produced in avian systems, both in hen’s eggs and increasingly in cultured cells. However, yields are often  limited by immune responses that can prevent the replication of vaccine viruses. 

The Pirbright Institute was first to describe a set of immune proteins in chickens, called chIFITMs, which interfere with viral replication in cells. The institute has now received a grant from the Livestock Vaccine Innovation Fund which is supported by the Bill & Melinda Gates Foundation, Global Affairs Canada, and Canada’s International Development Research Centre, to support the practical development of this research.  

Horizon will use its expertise in CRISPR/Cas9 gene editing to remove the chIFITM genes in chicken cells, thereby overcoming one of the main barriers for viral replication with the potential to boost the levels of vaccine virus produced between five and ten-fold.

Vaccines produced in avian systems represent an approximately $3.4 billion market1. A significant increase in yield may lead to a substantial decrease in manufacturing costs and pricing.  

The project is set to run for four years and this new technology could be commercially available by 2021.

Richard Vellacott (pictured), interim CEO and CFO at Horizon Discovery, said: “As a global leader in the application of gene editing to harness the power of the cell, Horizon is transforming the life sciences both in human biology and beyond.  

“We are now extending our biomanufacturing expertise into the agriculture market where there is an acute need to protect and improve yields, driven by a rapidly growing global population and increasing environmental pressures. 

“We are pleased to partner with The Pirbright Institute in this project which promises to have a significant impact on vulnerable populations worldwide.”

Newsletter Subscription

Stay informed of the latest news and features